Health · Pharma & Biotech · 7 hrs ago
Tegoprazan Reduced Heartburn Frequency in a Phase III Trial
A phase III trial found tegoprazan reduced heartburn frequency in people with non-erosive reflux disease, or NERD.
Participants took the medicine once a day as an oral pill.
Tegoprazan is a fast-acting potassium-competitive acid blocker, a type of medicine that reduces acid.
The finding concerns how often patients experienced heartburn, rather than a reported cure.
NERD is the condition named in the trial, and the results apply to patients with that diagnosis.
No further steps or trial details are provided in the available information.
A phase III trial found that tegoprazan significantly reduced heartburn frequency in patients with non-erosive reflux disease.
Participants took tegoprazan once daily.
Tegoprazan is described as a fast-acting oral potassium-competitive acid blocker.
- Who
- Patients with non-erosive reflux disease.
- What
- A phase III trial found that once-daily tegoprazan significantly reduced heartburn frequency.
- When
- Not stated
- Where
- Not stated
- Why
- Not stated
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Drug
- Tegoprazan
- Trial phase
- Phase III
- Condition
- Non-erosive reflux disease
- Dosing
- Once daily
- Drug class
- Oral potassium-competitive acid blocker